• Applications


    • Pharmaceuticals: Healthcare


Active Ingredients

HYPERKALIEMIA

Sodium Polystyrene Sulfonate USP AMBERLITE™ IRP69

Excess potassium in the blood is a common condition in chronic renal failure and is potentially life-threatening. The action of the functional polymer is simple ion exchange; the polymer is in the sodium form and the sodium ions are exchanged with the excess potassium in the blood stream as the resin passes through the GI tract. Typical dosage amounts are 15-60 g per day for extended periods of time. Formulations are either powder sachets or aqueous suspensions.

HYPERCHOLESTEROLEMIA

Cholestyramine Resin USP DUOLITE™ AP143 grades

Elevated levels of cholesterol is known to be an important factor in likelihood of cardiac arrests. Cholesterol is known to be a key intermediate in the biosynthesis of bile acids which are present in the GI tract. These bile acids can be bound to an anionic exchange resin and so effectively removing them from the body. This leads to replenishment of the bile acids through increased metabolism of cholesterol resulting in lowered serum cholesterol levels. Typical dosage amounts are 8-24g per day for extended periods. A number of different formulations are commercialised although the predominant one is a powder sachet or small container.

References:

  • Polli, Gerald P. and Shoop, Clyde E., (Merck and Co. USA), 1976. Palatable cholestyramine coacervate compositions. Patent US 3,974,272. Brauns H. A., Polli, Gerald P and Shoop, Clyde E., (Merck and Co., USA), 1974. Cholestyramine containing coacervate. Ger. Offen DE 2,344,090.
  • Kunin, Robert; Blood cholesterol reducing pharmaceutical composition; 1998; Patent US 5840339.
  • The cholesterol lowering effect of steroid sequestrants is modulated by large intestine fermentations, Corinne Moundrasa, *, Christian Demignéa, Andrzej Mazura and Christian Rémésya,The Journal of Nutritional Biochemistry Volume 6, Issue 3, March 1995, Pages 158-162.
  • Cholesterol - lowering therapy, TJ Andersona,Biomedecine & Pharmacotherapy, Volume 50, Issue 1, 1996, Page 40.
  • Combined drug therapy--cholestyramine and compactin--for familial hypercholesterolemia.Yamamoto A, Yamamura T, Yokoyama S, Sudo H, Matsuzawa Y. Int J Clin Pharmacol Ther Toxicol 1984 Sep 22:493-7
  • Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI type II coronary intervention study.,Brensike JF, Levy RI, Kelsey SF, et al. Circulation 1984; 69:313-24.